Literature DB >> 3994894

The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve.

P Fitzharris, A E McLean, R G Sparks, B C Weatherley, R D White, R Wootton.   

Abstract

BW12C, a potent left-shifting anti-sickling compound in vitro, was administered to normal healthy male Caucasian volunteers. Doses of 2-20 mg kg-1 given by intravenous infusion over 1 h caused a dose-dependent left-shift of the blood-oxygen saturation curve and at the highest dose some 16% of the haemoglobin existed in a high affinity form. Peak left-shift was observed at the end of infusion and decayed thereafter with a mean half-life of approximately 3 h. There were no adverse systemic effects, either clinical, biochemical or haematological, but there was some local irritation at the intravenous infusion site if the infusion was too concentrated. Pharmacokinetic measurements indicated uptake into erythrocytes, low levels in plasma and a volume of distribution not appreciably greater than the blood volume. A pilot radiolabel study indicated extensive metabolism with elimination into the urine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994894      PMCID: PMC1463810          DOI: 10.1111/j.1365-2125.1985.tb02672.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Preservation of deformability (filterability) of sickle cells by BW12C during progressive deoxygenation.

Authors:  M W Kenny; J Stuart
Journal:  Br J Haematol       Date:  1983-11       Impact factor: 6.998

2.  Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (second of three parts).

Authors:  J Dean; A N Schechter
Journal:  N Engl J Med       Date:  1978-10-12       Impact factor: 91.245

3.  Requirement for therapeutic inhibition of sickle haemoglobin gelation.

Authors:  H R Sunshine; J Hofrichter; W A Eaton
Journal:  Nature       Date:  1978-09-21       Impact factor: 49.962

4.  Sickle cell disease: the proportion of liganded haemoglobin needed to prevent crises.

Authors:  I M Franklin; M A Rosemeyer; E R Huehns
Journal:  Br J Haematol       Date:  1983-08       Impact factor: 6.998

5.  Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes.

Authors:  C R Beddell; P J Goodford; G Kneen; R D White; S Wilkinson; R Wootton
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

  5 in total
  14 in total

1.  Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. 5-7 April 1989, Bristol. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

2.  Proceedings of the British Pharmacological Society. Leeds, 12th-14th July 1989. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

3.  Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.

Authors:  Osheiza Abdulmalik; Mohini S Ghatge; Faik N Musayev; Apurvasena Parikh; Qiukan Chen; Jisheng Yang; Ijeoma Nnamani; Richmond Danso-Danquah; Dorothy N Eseonu; Toshio Asakura; Donald J Abraham; Jurgen Venitz; Martin K Safo
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-10-19

Review 4.  Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.

Authors:  Piyusha P Pagare; Aref Rastegar; Osheiza Abdulmalik; Abdelsattar M Omar; Yan Zhang; Andrew Fleischman; Martin K Safo
Journal:  Expert Opin Ther Pat       Date:  2021-11-01       Impact factor: 6.714

Review 5.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

6.  Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer.

Authors:  I F Dennis; J R Ramsay; P Workman; N M Bleehen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?

Authors:  Esther Oder; Martin K Safo; Osheiza Abdulmalik; Gregory J Kato
Journal:  Br J Haematol       Date:  2016-09-08       Impact factor: 6.998

8.  Characterization of the binding of the anti-sickling compound, BW12C, to haemoglobin.

Authors:  M Merrett; D K Stammers; R D White; R Wootton; G Kneen
Journal:  Biochem J       Date:  1986-10-15       Impact factor: 3.857

9.  Effects of 5-hydroxymethyl-2-furfural on the volume and membrane permeability of red blood cells from patients with sickle cell disease.

Authors:  Anke Hannemann; Urszula M Cytlak; David C Rees; Sanjay Tewari; John S Gibson
Journal:  J Physiol       Date:  2014-07-11       Impact factor: 5.182

10.  BW12C: effects on tumour hypoxia, tumour thermosensitivity and relative tumour and normal tissue perfusion in C3H mice.

Authors:  D J Honess; D E Hu; N M Bleehen
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.